IceCure Medical Reports First Half 2023 Financial & Operational Results: Global Adoption of Cryoablation Technology Gaining Momentum

IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2023, as well as operational and recent corporate developments.

Related Keywords

India ,Portugal ,United States ,Japan ,Paris ,France General ,France ,Kovai ,Tamil Nadu ,Israel ,Brazil ,Canada ,China ,Israeli ,Canadian ,Todd Kehrli ,Eyal Shamir ,Michael Polyviou ,China National Medical Products Administration ,Sorbonne University Department Of Interventional Radiology ,Company Prosense ,Kovai Medical Center ,Israel International ,Company Icesense ,Drug Administration ,Company Annual Report On Form ,Health Canada ,Terumo Corporation ,World Health Organization ,Second Quarter Highlights ,Icecure Chief Executive Officer ,Recent Operating ,Sense Used ,American Society ,Breast Surgeons ,Annual Meeting ,Ever Course ,Approvals Received ,Prosense System ,National Medical Products Administration ,Upfront Sales ,Leading Hospital ,Offer Breast Cancer Cryoablation ,Avoiding Secondary Surgery Reported ,Study That Used Prosense ,Interventional Radiology ,Sorbonne University Department ,Tenon Hospital ,Six Months Ended ,Cure Medical ,Private Securities Litigation Reform Act ,Risk Factors ,Annual Report ,Prosense ,Kryoablation ,Icecure Medical Ltd ,